Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model

Sheng Fan Wang, Sung Pin Tseng, El Wui Loh, Wen Hung Wang, Ming Chun Li, Kuan Hsuan Chen, Wan Chi Tsai, Yuan Ming Lee, Huan Yuan Chen, Fu Tong Liu, Yi Ming Arthur Chen, Jason C. Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In 2009, a swine-origin influenza A virus – A(H1N1)pdm09 – emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-“STAS” and “FRSK” which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009–2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.

Original languageEnglish
Pages (from-to)8-17
Number of pages10
JournalDevelopmental and Comparative Immunology
Volume67
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

H1N1 Subtype Influenza A Virus
Monoclonal Antibodies
Hemagglutinins
Oseltamivir
Therapeutics
Baculoviridae
Therapeutic Uses
Pandemics
Orthomyxoviridae
Viral Load
Human Influenza
Insects
Epitopes
Immunization
Coloring Agents
Cytokines
Lung

Keywords

  • Epitope
  • H1N1
  • Influenza virus
  • Monoclonal antibody
  • Prophylactic
  • Therapeutic
  • Trimeric hemagglutinin

ASJC Scopus subject areas

  • Immunology
  • Developmental Biology

Cite this

Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model. / Wang, Sheng Fan; Tseng, Sung Pin; Loh, El Wui; Wang, Wen Hung; Li, Ming Chun; Chen, Kuan Hsuan; Tsai, Wan Chi; Lee, Yuan Ming; Chen, Huan Yuan; Liu, Fu Tong; Arthur Chen, Yi Ming; Huang, Jason C.

In: Developmental and Comparative Immunology, Vol. 67, 01.02.2017, p. 8-17.

Research output: Contribution to journalArticle

Wang, Sheng Fan ; Tseng, Sung Pin ; Loh, El Wui ; Wang, Wen Hung ; Li, Ming Chun ; Chen, Kuan Hsuan ; Tsai, Wan Chi ; Lee, Yuan Ming ; Chen, Huan Yuan ; Liu, Fu Tong ; Arthur Chen, Yi Ming ; Huang, Jason C. / Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model. In: Developmental and Comparative Immunology. 2017 ; Vol. 67. pp. 8-17.
@article{07df5368c77b447bbea2ca14cf237a25,
title = "Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model",
abstract = "In 2009, a swine-origin influenza A virus – A(H1N1)pdm09 – emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-“STAS” and “FRSK” which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009–2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.",
keywords = "Epitope, H1N1, Influenza virus, Monoclonal antibody, Prophylactic, Therapeutic, Trimeric hemagglutinin",
author = "Wang, {Sheng Fan} and Tseng, {Sung Pin} and Loh, {El Wui} and Wang, {Wen Hung} and Li, {Ming Chun} and Chen, {Kuan Hsuan} and Tsai, {Wan Chi} and Lee, {Yuan Ming} and Chen, {Huan Yuan} and Liu, {Fu Tong} and {Arthur Chen}, {Yi Ming} and Huang, {Jason C.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.dci.2016.10.010",
language = "English",
volume = "67",
pages = "8--17",
journal = "Developmental and Comparative Immunology",
issn = "0145-305X",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model

AU - Wang, Sheng Fan

AU - Tseng, Sung Pin

AU - Loh, El Wui

AU - Wang, Wen Hung

AU - Li, Ming Chun

AU - Chen, Kuan Hsuan

AU - Tsai, Wan Chi

AU - Lee, Yuan Ming

AU - Chen, Huan Yuan

AU - Liu, Fu Tong

AU - Arthur Chen, Yi Ming

AU - Huang, Jason C.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - In 2009, a swine-origin influenza A virus – A(H1N1)pdm09 – emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-“STAS” and “FRSK” which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009–2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.

AB - In 2009, a swine-origin influenza A virus – A(H1N1)pdm09 – emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-“STAS” and “FRSK” which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009–2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.

KW - Epitope

KW - H1N1

KW - Influenza virus

KW - Monoclonal antibody

KW - Prophylactic

KW - Therapeutic

KW - Trimeric hemagglutinin

UR - http://www.scopus.com/inward/record.url?scp=84994558787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994558787&partnerID=8YFLogxK

U2 - 10.1016/j.dci.2016.10.010

DO - 10.1016/j.dci.2016.10.010

M3 - Article

C2 - 27984103

AN - SCOPUS:84994558787

VL - 67

SP - 8

EP - 17

JO - Developmental and Comparative Immunology

JF - Developmental and Comparative Immunology

SN - 0145-305X

ER -